TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive Private Institute Commits $1 Million Pick Up some NIH Grants Left Unfunded April 19, 1985